Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Description
CONCLUSION: The fourth dose of the COVID-19 vaccine appears to be highly immunogenic and safe in allogeneic HSCT patients. Further studies are needed to determine the neutralizing antibody titers against SARS-CoV-2 subvariants and the effectiveness
